Ekf Diagnostics Dividends - EKF

Best deals to access real time data!
Level 2 Basic Monthly Subscription for only ~~£62.08~~
Silver Monthly Subscription for only ~~£17.37~~
UK/US Silver Monthly Subscription for only £30.59
VAT not included

Stock Name	Stock Symbol	Market	Stock Type	Stock ISIN	Stock Description
Ekf Diagnostics Holdings Plc	EKF	London	Ordinary Share	GB0031509804	ORD 1P

	Price Change	Price Change %	Stock Price	Last Trade
	0.60	0.76%	79.40	16:35:01

Open Price	Low Price	High Price	Close Price	Previous Close
79.40	78.60	80.80	79.40	78.80

more quote information »

Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Ekf Diagnostics EKF Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
14/09/2020	Interim	GBX	1	30/12/2019	30/06/2020	04/11/2020	05/11/2020	01/12/2020	0

Top Dividend Posts

Date	Subject
10/4/2021 15:09	wan: Nurdin...Whilst Mr Stewart for the Daily Mail clearly recognises the history of success from the management team over some years, he makes no reference to that in any detail. With perhaps good reason if you are hoping to buy in at a cheaper price! As I said in several recent posts, there are indeed a number of reasons beyond the metrics (that indicate a full price) to be bullish on EKF. Some of these are well covered in Hastings write-up. Furthermore, looking beyond the financial metrics that JUS is obviously relying on or indeed implying, how does one value the agreement and relationship with Mount Sinai? This agreement and relationship provides EKF with advanced access to innovative commercial opportunities and presents significant opportunity for EKF to collaborate on ground breaking medical technologies that can be spun off and proceed down the IPO route. This has already resulted in shareholders benefiting from owning shares via a dividend in-specie in the spin off, Renalytix (price at IPO £1.21 per share, share price now circa £10) and now Verici (if you kept your Renalytix shares with a current share price of circa 60p and in which EKF have received 2,677,981 shares), with Trellus Health next in line for an IPO. However, the management are aiming to replicate this process further with at least one investment and IPO per year. Not two a penny, as these things take time, but if you were only focused on certain financial metrics (as perhaps JUS implies), then you wouldn't have been invested in EKF any earlier either to have benefited from what is arguably difficult to measure. And I would suggest that Mr Stewart has likewise been unable to measure this aspect either.........however, arguably it must surely be worth at least some form of premium to get such exposure? The managements track record in terms of delivery (not just the IPO's) is very encouraging indeed, and JUS has at least 'tentatively' recognised that fact! And this is before I get into EKF's close-knit relationship with their new private sector partner (believed to be Amazon) and who's logistical expertise and ambitions extend 'far beyond' testing just their own employees (and with over 1 million employees this on its own should not be underestimated). Read Full Thread Follow Reply
10/4/2021 06:37	wan: It looks like JUSTIN URQUHART STEWART FOR THE DAILY MAIL, likes EKF, but he hopes he can buy it cheaper, but he clearly does not fully appreciate what else is under EKF's bonnet (nor appreciates who EKF's private partner is and how that relationship might evolve, or perhaps even hoping it's not actually revealed anytime soon). Time will tell, but he might do well to read Hastings excellent and most recent coverage - EKF - A HEALTHY INVESTMENT - 09/03/21 Whilst the huge level of success from its PrimeStore offering has been the key driver of EKF’s share price over the last year, there continues to be much more on offer here. Full article - hTTps://martinflitton1.wixsite.com/privatepunter/post/ekf-a-healthy-investment-09-03-21 The Daily Mail piece - MR MONEY MAKER: EKF Diagnostics has the kit to give your portfolio a shot in the arm By JUSTIN URQUHART STEWART FOR THE DAILY MAIL PUBLISHED: 21:50, 9 April 2021 Any suggestions? So I like to look for history of success from the team over some years. EKF Diagnostics certainly has this, but the price is quite full. I would prefer to keep it on the watch list and wait for a pullback, which will be coming in the not too distant future. Full story - hTTps://www.thisismoney.co.uk/money/investing/article-9454835/MR-MONEY-MAKER-EKF-Diagnostics-boost-portfolio.html As I said previously, there are indeed other reasons to be bullish on EKF (more of which later), and thus in my view there will likely be plenty of investors in the wings hoping to buy before upgrades (given the current broker conservatism), or on any weakness. JUS is clearly one one of those, and to a degree, talking it down to help achieve that. Importantly though, and as a consequence, any meaningful weakness (if it materialises) might be very short lived! Read Full Thread Follow Reply
01/4/2021 15:55	wan: Jacks13...The following possibly provides some useful insight - 12 Jan, 2021 Amazon is likely to boost its own healthcare ambitions after exiting Haven JV Amazon.com Inc., JPMorgan Chase & Co. and Berkshire Hathaway Inc. are calling it quits on their healthcare joint venture, but the e-commerce company is forging ahead with solo ambitions in the healthcare space and will likely apply the knowledge it obtained from working with its soon-to-be former partners, according to health industry experts and analysts. Experts say the e-commerce company can use what it has learned from the Haven experience and apply insights to healthcare programs in areas like telehealth and negotiations with healthcare providers. Over the past three years, Amazon has introduced new ways to deliver care, including the Amazon Care virtual and in-person health clinic that debuted in 2019 for employees in the Seattle area and Amazon Pharmacy, an online pharmacy platform the company launched in November 2020 that offers prescription delivery and drug price transparency. Amazon could also pilot new programs that incentivize employees to lower their own healthcare spend, experts say. "Amazon absolutely has a great opportunity to make a success of their healthcare ambitions on their own than through Haven," said Paddy Padmanabhan, founder and CEO of Damo Consulting, a growth strategy and digital transformation advisory firm that works with healthcare enterprises and global technology companies, in an interview. "I never saw Amazon sort of hitching their healthcare wagon to Haven at any point." But the disbandment of Haven highlights the difficulties of disrupting a fragmented and highly regulated industry dominated by large incumbent players such as CVS Health Corp. and Walgreens Boots Alliance Inc. and rife with complexities, including a vast web of middlemen and insurance companies, experts say. "It's a very complex and unique business model that these three groups had never necessarily been in the weeds on," said Paul Ceverha, managing director in the healthcare practice at AArete, in an interview. Lessons learned With insights gained through Haven, Amazon can leverage its workforce of more than 1 million employees and ability to reach millions of paid Prime subscribers to test new programs in areas ranging from insurance plans to telehealth services, a growing arena of opportunity as the pandemic has led consumers to avoid receiving in-person healthcare services. "They are well-equipped and have tons of experience and exceptional execution on supply chain issues," said Ceverha. U.S. telehealth services industry revenue has grown significantly over the past five years to $3.22 billion as of 2020, according to IBIS World. Full story - hTTps://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/amazon-is-likely-to-boost-its-own-healthcare-ambitions-after-exiting-haven-jv-62000298 Yep, Amazon could easily buy EKF (they have already acquired some health related businesses), but given the deal thus far, partnering is obviously the preferred choice with EKF (and Longhorn). EKF's Life Science business could offer and indeed provide a 'lot' more than just the current deal for PBS. Also, there is a lot more under EKF's bonnet than first glance reveals, such as specialist knowledge and relationships, which could be very useful in realizing some of Amazons ambitions, such as EKF's Preferred partnership agreement with Mount Sinai Innovation Partners that provides EKF with advanced access to innovative commercial opportunities arising from Mount Sinai Health System (MSHS) owned technologies managed by MSIP in the field of digital healthcare. Not everything can or should be bought outright, sometimes partnering can offer a better platform to realizing ambitions and growth! And as outlined in the above article, given some of the complexities that Amazon has experienced, may be they are content with a strong EKF partnership for the foreseeable, and not to mention what benefits Amazons exceptional supply chain and logistics will bring into the equation! Read Full Thread Follow Reply
03/3/2021 07:36	wan: An interesting comparison - Last years Notice of FY Results announcement contained the following description - About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Notice-of-Results/81906145 Todays announcement contains the following description - About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF Diagnostics Holdings plc specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products. In 2020, EKF developed a range of COVID-19 testing products including PrimeStore MTM, an FDA-approved and CE marked sample containment device that allows the safe handling, transportation and analysis of test swabs and samples, which it manufactures under licence, and COVID-SeroKlir, a leading ELISA-based antibody test from Kantaro Biosciences that provides a precise measurement of COVID-19 IgG antibodies. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Notice-of-Results/84481970 In my opinion only, this further supports my view that PrimeStore products will become core EKF products i.e. in constant use for the foreseeable (as perhaps exemplified by SBI's expansion in the US), and in that I also include country surveillance and preparedness. Read Full Thread Follow Reply
16/2/2021 07:38	wan: Melody...the relevant announcement/details - On 11 December 2020 the board of EKF (the “Board”) convened and declared a dividend in specie of shares in Trellus to trustees, to be held on trust for the Company's shareholders (the "Dividend"). EKF’s investment in Trellus comprises 27,999,999 A Shares of £0.0001 each and 1 golden share of £0.0001 (the "Golden Share"). The Golden Share is the voting share in the capital of Trellus and will be retained by the Company. The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share held in the Company. Relevant EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited (“Broadway”), at which time an ‘omnibus’ share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of: 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled (the “Lock-up Period”). During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares. Full details - hTTps://www.ekfdiagnostics.com/approval-of-dividend-in-specie-of-investment-in-trellus-health.html Read Full Thread Follow Reply
16/2/2021 07:07	pldazzle: boadicea - Sadly HMRC won't wear your suggestion. Remittance basis can't apply to income arising in the UK, which this is by definition in that EKF (the payer) is itself a UK company. You ask "how is the dividend to be paid if they cannot be liquidated". The answer is that it has already been paid, specifically on 18/12/20, but being in specie it hasn't been (and won't be) paid in cash. Tough perhaps on individual large shareholders, particularly any who have little or no other income, though these will be very few in number and in practice I suspect the issue will be largely academic. [Edit - following paragraph inserted:] To put that in perspective, a holder of 100K EKF (currently worth c£75,000) would have received a dividend of 6153 Trellus shares. If these are valued at say 25p per share at 18/12/20 (only my own guess!) that would work out at £1,536. No other income? Unusual, as EKF has also paid a cash dividend of 1p per share: but at all events, the first £2,000 of dividends is tax-free. 45% taxpayer? Should be no problem finding £692, if necessary just sell a few EKF shares..... On the other hand, (a) I have seen a suggestion - infuriatingly I can no longer find the link and don't know how accurate it is - that the IPO is expected in calendar Q2 2021 (i.e. between April and June this year). That being the case, the lock-up should be over only a few months after the tax is technically due; and (b) if the experience with RENX is anything to go by, the price at admission should be several times the value of the dividend at the time of in-specie payment. I have been assured by the company that the value of the dividend is to be announced with the final 2020 results, due next month or shortly after. Read Full Thread Follow Reply
28/1/2021 14:35	rivaldo: NIce feature today on the expansion in Cardiff: Https://www.insidermedia.com/news/wales/ekf-expands-into-second-manufacturing-facility-in-cardiff "EKF expands into second manufacturing facility in Cardiff 28 Jan 2021 EKF Diagnostics has expanded its production with the introduction of a new manufacturing facility in Cardiff. The expansion is to help the listed business meet demand for PrimeStore MTM, a key component of the Covid-19 testing process. PrimeStore MTM allows Covid-19 samples from swabs to be rapidly inactivated in the collection tube, enabling safe transportation and avoiding contamination while preserving RNA for accurate analysis without the need for refrigeration. The new facility is more than 600 sq. metres, representing a 100 per cent increase in manufacturing space. Up to 36,000 PrimeStore MTM tubes will be produced at Llandough every day, adding to EKF’s existing manufacturing onsite at Penarth and at its three other facilities in Texas and Indiana in the US, and Barleben, Germany. EKF engaged only local contractors during the fitting out process and now finished, the new facility at Llandough will provide work for up to 40 staff, operating three tube filling pump lines and three rooms for sample kit assembly. Already EKF has created over 30 new jobs on the production line and in quality assurance, customer services, purchasing, operations and logistics to meet the demand for PrimeStore MTM. EKF expects to employ more staff as it settles into the new facility. EKF’s continued growth, has created opportunities for many other new employees from a diverse range of Covid-19 impacted industries. The new manufacturing facility will also become a distribution hub for EKF’s latest portfolio addition, Covid-SeroKlir which is an antibody test developed by Kantaro Biosciences based on technology from Mount Sinai Health System in New York. EKF chief executive Julian Baines said: "We are proud to be bucking the current employment trend in Wales by taking this strategic decision to increase the size of our manufacturing facilities in Cardiff. We could have stayed in our previous manufacturing space but by moving into larger facilities we have room for growth and can ensure our growing staff numbers can operate in a safe and secure environment." He added: "Although Covid-19 vaccines are being rolled out, we are still experiencing strong demand from both public and private sector customers for PrimeStore MTM. "We are also about to launch our new Covid-19 antibody testing kit which we believe will also be of interest to labs, hospitals and businesses who want to identify which members of staff have antibodies. Those with a high antibody count will have strong resistance to the virus and with regular monitoring can return to the workplace." Read Full Thread Follow Reply
22/1/2021 06:04	wan: Testing, testing, testing! The attributes of PrimeStore appears to be coming evermore to the fore, not to mention EKF's excellent customer service - 21st January 2021 EKF opens larger facility to increase production of key component for COVID-19 testing regime EKF’s new facilities in Llandough, Cardiff, for manufacture of PrimeStore® MTM viral transport media, enabling pathogenic samples to be collected and transported safely and easily in compliance with UN3373 packaging regulations. EKF Diagnostics, the global in vitro diagnostics company, announces that it has expanded into new larger manufacturing facilities at Llandough Trading Estate, Cardiff, to increase production of PrimeStore® MTM viral transport media, a key component for the COVID-19 testing regime. The new facility is over 600 sq. metres, representing a 100% increase in manufacturing area. This enables EKF to fill 36,000 PrimeStore MTM tubes daily and meet growing UK and EU demand for this novel, patented sample collection device successfully evaluated for effective SARS-CoV-2 inactivation by Public Health England [1]. Already an established device for safe and easy transportation of pathogenic samples, millions of PrimeStore MTM tubes have now been sold globally during the SARS-CoV-2 pandemic; and EKF continues to receive escalating numbers of orders from healthcare, education and industry for COVID-19 testing programmes. As well as the additional manufacturing capacity in Wales, EKF has also increased production at its facilities in Barleben, Germany, and USA in Boerne, Texas, and South Bend, Indiana. The new Cardiff facility will also become a distribution hub for EKF’s latest portfolio addition, the Kantaro COVID-SeroKlir SARS-CoV-2 IgG antibody test kit and provide more space for new product development in the laboratories at EKF’s Headquarters in Penarth, Cardiff. In addition to the increased floor space, EKF has grown its workforce at a time when many companies in Wales are sadly being forced to make redundancies. The new facility, fitted out using only local contractors, can accommodate up to 40 staff operating three tube filling pump lines and three rooms for sample kit assembly. Already EKF has created over 30 new jobs, including production line operatives, and in quality assurance, customer services, purchasing, operations and logistics to meet the demand for PrimeStore MTM. EKF expects to employ more staff in the short term as it settles into the new facility. The success of PrimeStore that has necessitated the increased production capacity is due to new high-volume customers, as well as increasing orders from current customers finding that it is helping them to significantly streamline their sample collection and testing processes. This is because the novel sample collection device allows COVID-19 samples from swabs to be rapidly inactivated in the collection tube, avoiding contamination whilst preserving RNA with no requirement for refrigeration. Removing the need for cold chain storage and enabling immediate testing without need for containment in the laboratory delivers cost, efficiency and safety advantages. Leicester University has established an asymptomatic SARS-CoV-2 screening programme to support and reassure staff and students on campus, and reduce viral transmission. “By choosing PrimeStore MTM with its viral inactivation properties, we are ensuring the safe transportation and processing of participants’ samples and ensuring protection for our staff,” said Dr Rebecca Allsopp, Research Associate at Leicester Cancer Research Centre, University of Leicester. “We have the reassurance of RNA stabilisation, protecting sample integrity at room temperature without the need for additional storage requirements. EKF has also provided excellent customer service.” PrimeStore MTM (Molecular Transport Medium) was specifically designed and optimized for molecular testing allowing pathogenic samples to be collected, transported, and processed safely and efficiently. The molecular transport medium inactivates infectious biological pathogens including viruses (such as SARS-CoV-2 and flu A & B), and gram-positive/negative bacteria whilst preserving and stabilizing labile DNA and RNA for downstream molecular applications under standard laboratory conditions. Full release - hTTps://www.ekfdiagnostics.com/ekf-opens-larger-facility-to-increase-production-of-key-component-for-covid-19-testing-regime.html I also very much like that the expansion will free up and enable new product development in the laboratories at EKF’s Headquarters in Penarth, Cardiff. Read Full Thread Follow Reply
13/1/2021 14:35	srichardson8: part of the staement from my broker and possibly on the EKF website 'EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited, at which time an `omnibus` share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled. During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares.' Read Full Thread Follow Reply
14/12/2020 07:31	masurenguy: 14 December 2020: Approval of dividend in specie of investment in Trellus Health "Approval by shareholders was granted at the General Meeting held on 10 December 2020, to distribute the Company's entire holding of A Ordinary Shares in Trellus ("A Shares") by way of a dividend in specie to EKF Shareholders on the register at 17 December 2020. The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share held in the Company. Relevant EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited ("Broadway"), at which time an 'omnibus' share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of: -- 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or -- if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled (the "Lock-up Period"). During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares. Relevant EKF Shareholders will receive a letter informing them of their beneficial holdings of Dividend Shares shortly after the transfer of the Dividend Shares to Broadway. Following the Lock-up Period, Relevant EKF Shareholders will receive individual certificates in respect of their Dividend Shares. Read Full Thread Follow Reply

Advertise Here

Your Recent History

LSE

EKF

Ekf Diagno..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20210417 05:54:43